# US 10,864,282 B2 · ST-246 liquid formulations and methods

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,864,282 B2
- Document ID: US10864282B2
- Status: Granted
- Kind: B2
- Application number: 16/732,509
- Filed: 2020-01-02
- Published: 2020-05-07
- Granted: 2020-12-15
- Earliest claimed: 2010-08-05
- Assignees: Siga Technologies, Inc.
- Applicants: Siga Technologies, Inc.
- Inventors: Shanthakumar R. Tyavanagimatt; Melialani A. C. L. S. Anderson; William Weimers; Gopi Krishna Kasi; N K Peter Samuel; Tove C. Bolken; Dennis E. Hruby
- Web page: https://patentgrep.com/patent/US10864282B2

## CPC

- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/4035: Isoindoles, e.g. phthalimide
- A61K 31/715: Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K 31/724: Cyclodextrins
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 31/12: Antivirals
- A61P 31/20: for DNA viruses
- C12N 2710/24071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides for a novel liquid formulation for solubilizing poorly soluble ST-246 in cyclodextrins and a novel process of making the formulation.

## Claims

### Claim 1

A process for preparing a water-soluble solid ST-246 pharmaceutical formulation comprising:
a) mixing ST-246 with cyclodextrin in a pharmaceutically acceptable liquid carrier;
b) optionally filtering the mixture of step a); and
c) lyophilizing said mixture.

### Claim 2 (depends on 1)

The process of claim 1, wherein said cyclodextrin is hydroxypropyl-β-cyclodextrin and/or sulfobutyl-ether-β-cyclodextrin.